SuperworthCitius Oncology EPS CTOR
Diluted earnings per share by quarter and over the last twelve months, from 2022.
- Last 12 months, to Jun 30, 2026
- −$0.47
- Latest quarter, Q3 FY26
- −$0.08
- Fiscal year 2025
- −$0.34
Citius Oncology's earnings per share was −$0.47 over the twelve months to Jun 30, 2026.
In its latest quarter, Q3 FY26, it was −$0.08.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.34 | n/a |
| FY2024 | −$0.31 | −444% |
| FY2023 | $0.09 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | −$0.08 | n/a | −$0.47 | |
| Q2 FY26 | −$0.27 | n/a | −$0.47 | |
| Q1 FY26 | −$0.06 | n/a | −$0.31 | |
| Q4 FY25 | −$0.06 | n/a | −$0.34 | |
| Q3 FY25 | −$0.08 | n/a | −$0.38 | |
| Q2 FY25 | −$0.11 | n/a | −$0.37 | |
| Q1 FY25 | −$0.09 | n/a | −$0.33 | |
| Q4 FY24 | −$0.10 | n/a | −$0.31 | |
| Q3 FY24 | −$0.07 | −450% | −$0.19 | |
| Q1 FY24 | −$0.07 | −200% | −$0.05 | |
| Q4 FY23 | −$0.07 | n/a | $0.09 | |
| Q3 FY23 | $0.02 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Citius Oncology's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CTORCitius Oncology | −$0.47 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Citius Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.